Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
ORIGIN
ORIGIN IgAN Study
Brief Description
The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.
Trial Physician / Study Coordinator
Gemma Hector
EmailSite Name
Kent and Canterbury Hospital
Ethelbert Road, Canterbury – Kent CT1 3NG, United Kingdom
Sponsor
Vera Therapeutics
Study Drug
atacicept
Estimated enrollment
105 participants
Estimated end date
The estimated end date of enrollment of the study is in the second quarter of 2022
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
ORIGIN
ORIGIN IgAN Study
Brief Description
The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.
Trial is for people with
A diagnosis of IgAN confirmed by a kidney biopsy with the past 10 years who are on a stable, prescribed regimen of an RAASi (for example, ACE/ARB) medication for at least 12 weeks.
What is involved for the Patient?
Complete assessment like physical exams, blood tests and 24 hour urine. Patients will be assigned to receive active study medication or placebo. There is a 70% chance of being assigned to receive active study mediation. Receive once-weekly injections (at the clinic or at home). Attend clinic visits over the course of 9 months. After completing the 9 months all participants will be able to receive active study medication for an additional 60 weeks.
About the drug or intervention
Atacicept is designed to help prevent the buildup of IgA in the kidneys by controlling the immune response that causes IgAN.